The development of oral insulin-sensitizing agents to minimize the need for injectable insulin remains a major unmet need in the treatment of diabetes. Now, writing in Nature Chemical Biology, Bottini and colleagues report the identification of the first orally available small-molecule inhibitor of the low-molecular-weight phosphotyrosine protein phosphatase (LMPTP), which enhance…
